PARIS, November 13, 2024--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME ...

GenSight Biologics is weeks away from running out of money. Again. The biotech only has enough cash to fund operations into mid-November and, with a revenue stream set to start later than planned ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a ...

PARIS, October 17, 2024--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing ...

"We are truly grateful for the continuing support of Heights Capital and Sofinnova Partners,” noted Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics. “The small bridge ...

In a report released on November 13, Justine Telliez from Kepler Capital maintained a Hold rating on GenSight Biologics SA (G49N – ...

This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia GenSight ...

1 Day GSGTF 0.00% DJIA 0.76% Russell 2K 1.54% Health Care/Life Sciences -0.41% ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.